Latest Property Portfolio News

Mesoblast Limited reports a robust 66% increase in Ryoncil revenues for Q2 2025, driven by strong market adoption and new Medicare reimbursement codes.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

Hazer Group has been granted a pivotal patent in Singapore for its proprietary graphite morphology process, reinforcing its foothold in Southeast Asia's clean energy and advanced manufacturing markets.

CAQ Holdings Limited reported a 29.6% revenue decline and a 43.9% increase in net loss for the half-year ended June 2025, driven largely by falling investment property values and ongoing liquidity challenges.

Desane Group Holdings has sold its commercial property at 13 Sirius Road, Lane Cove for $8.7 million, marking a strategic shift to fund future growth opportunities.

Mesoblast has entered agreements to issue up to US$50 million in convertible notes, aiming to strengthen its capital base and support pipeline growth, pending shareholder approval.

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

DGL Group reported a modest revenue rise but faced a significant earnings dip in FY25, driven by losses in its Environmental division and restructuring costs. The company is now focusing on integration and operational efficiencies to rebound in FY26.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.